High and Low Levels of an NTRK2-Driven Genetic Profile Affect Motor- and Cognition-Associated Frontal Gray Matter in Prodromal Huntington's Disease.

brain sciences Article High and Low Levels of an NTRK2-Driven Genetic Profile Affect Motor- and Cognition-Associated Frontal Gray Matter in Prodromal Huntington’s Disease Jennifer A. Ciarochi 1 ID , Jingyu Liu 2 , Vince Calhoun 2,3 , Hans Johnson 4 ID , Maria Misiura 5 , H. Jeremy Bockholt 2 , Flor A. Espinoza 2 , Arvind Caprihan 2 , Sergey Plis 2 , Jessica A. Turner 1,5, *, Jane S. Paulsen 4,6,7 ID and the PREDICT-HD Investigators and Coordinators of the Huntington Study Group † 1 2 3 4 5 6 7 * † Neuroscience Institute, Georgia State University, Atlanta, GA 30302, USA; The Mind Research Network, Albuquerque, NM 87106, USA; (J.L.); (V.C.); (H.J.B.); (F.A.E.); (A.C.); (S.P.) Department of Electrical and Computer Engineering, University of New Mexico, Albuquerque, NM 87131, USA Iowa Mental Health Clinical Research Center, Department of Psychiatry, University of Iowa, Iowa City, IA 52242, USA; (H.J.); (J.S.P.) Department of Psychology, Georgia State University, Atlanta, GA 30302, USA; Department of Neurology, University of Iowa, Iowa City, IA 52242, USA Department of Psychology, University of Iowa, Iowa City, IA 52242, USA Correspondence: ; Tel.: +1-404-413-6211 Detailed information in Author Contribution part. Received: 16 May 2018; Accepted: 20 June 2018; Published: 22 June 2018



 Abstract: This study assessed how BDNF (brain-derived neurotrophic factor) and other genes involved in its signaling influence brain structure and clinical functioning in pre-diagnosis Huntington’s disease (HD). Parallel independent component analysis (pICA), a multivariate method for identifying correlated patterns in multimodal datasets, was applied to gray matter concentration (GMC) and genomic data from a sizeable PREDICT-HD prodromal cohort (N = 715). pICA identified a genetic component highlighting NTRK2, which encodes BDNF’s TrkB receptor, that correlated with a GMC component including supplementary motor, precentral/premotor cortex, and other frontal areas (p < 0.001); this association appeared to be driven by participants with high or low levels of the genetic profile. The frontal GMC profile correlated with cognitive and motor variables (Trail Making Test A (p = 0.03); Stroop Color (p = 0.017); Stroop Interference (p = 0.04); Symbol Digit Modalities Test (p = 0.031); Total Motor Score (p = 0.01)). A top-weighted NTRK2 variant (rs2277193) was protectively associated with Trail Making Test B (p = 0.007); greater minor allele numbers were linked to a better performance. These results support the idea of a protective role of NTRK2 in prodromal HD, particularly in individuals with certain genotypes, and suggest that this gene may influence the preservation of frontal gray matter that is important for clinical functioning. Keywords: Huntington’s disease; brain-derived neurotrophic factor; tropomyosin receptor kinase B; supplementary motor; independent component analysis Brain Sci. 2018, 8, 116; doi:10.3390/brainsci8070116 www.mdpi.com/journal/brainsci Brain Sci. 2018, 8, 116 2 of 24 1. Introduction 1.1. Huntington’s Disease Huntington’s disease (HD) is a progressive, heritable condition characterized by chorea (involuntary motion) as well as cognitive alterations spanning executive functioning, working memory, olfactory and facial recognition, and emotional processing [1]. HD, along with Alzheimer’s disease (AD) and Parkinson’s disease (PD), is a proteinopathy distinguished by regionally-selective neuronal death and protein misfolding that manifests as expanded huntingtin in HD, Lewy bodies in PD, and β-amyloid plaques in AD [2]. Unfortunately, across these conditions limited treatment options and no known cures are available. However, their shared features have sparked speculation about common underlying mechanisms, and the delayed-onset of these disorders raises the appealing possibility of developing treatments that postpone onset indefinitely, effectively eradicating the disease. A promising way to identify treatment targets is to characterize the earliest changes before the onset of HD. Motor impairments associated with HD, such as dystonia and chorea, often lead to diagnosis because their disruptiveness prompts affected individuals to seek medical attention. However, cognitive symptoms and alterations in brain volume and morphology are already present more than a decade before diagnosis, during a period known as the prodrome [3]. In keeping with this, PREDICT-HD is a multi-site research study aiming to identify the earliest changes in the HD prodrome, with the hopes of identifying targets for the earliest possible interventions [3]. PREDICT-HD has amassed a comprehensive dataset of genomic, structural and functional magnetic resonance imaging (MRI and fMRI), diffusion tensor imaging (DTI), cognitive and motor assays, cytosine-adenine-guanine (CAG)-repeat information, and demographic variables from over 1449 prodromal HD and control participants, including longitudinal data from over 900 participants. Although there is no cure for HD, its cause is known. An abnormally large cytosine-adenine-guanine (CAG) expansion (≥36 repeats) at an HTT exon 1 locus determines future HD development. The HTT gene encodes huntingtin protein, which is widely expressed in the brain and central nervous system [4]. Abnormally-expanded HTT encodes mutant huntingtin (mHTT), which compromises numerous cellular processes including endocytosis and secretion, calcium homeostasis [5], glutamatergic synaptic functioning [6], vesicular transport [7], mitochondrial functioning [8], p53 signaling [7], apoptosis, and transcription [9]. 1.2. Effects of Multiple Genes and Variants Both within and outside the realm of huntingtin’s interactions, several lines of evidence implicate non-HTT factors as modulators of prodromal progression and HD onset. Moreover, the reduced genetic complexity of HD makes it tractable to disentangle onset-protection and susceptibility factors. HTT CAG-expansion length considerably influences age at diagnosis and can be used to estimate the age of, or time to, HD onset. Despite strong prediction accuracy for many prodromal individuals, some outcomes deviate from expectations. For example, one PREDICT-HD participant with 44 CAG-repeats lacked positive diagnosis at the age of 71 years, and 13 participants with <41 repeats reached the age of 70 years with no diagnosis. HD onset prediction (based on age and CAG-repeat number) is most accurate in individuals with >44 repeats and increasingly variable as the repeat number decreases, and different disease progression rates are often observed in persons with the same number of CAG-repeats. These examples highlight the onset variability and suggest that additional genetic factors may promote or suppress HD conversion (especially at lower CAG-repeat numbers), yet little is known about non-HTT genetic factors that account for variability in the rapidity and severity of HD symptoms and onset. The influence of such fa (...truncated)